KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals has reported Other Operating Expenses over the past 15 years, most recently at $65.3 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 46.07% to $65.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.4 million through Dec 2025, up 26.48% year-over-year, with the annual reading at $189.4 million for FY2025, 26.48% up from the prior year.
  • Other Operating Expenses was $65.3 million for Q4 2025 at Supernus Pharmaceuticals, up from $43.3 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $65.3 million in Q4 2025 and troughed at $22.2 million in Q2 2021.
  • The 5-year median for Other Operating Expenses is $41.3 million (2021), against an average of $40.6 million.
  • Year-over-year, Other Operating Expenses surged 662.26% in 2021 and then decreased 26.34% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $30.1 million in 2021, then soared by 36.86% to $41.2 million in 2022, then surged by 47.11% to $60.7 million in 2023, then decreased by 26.34% to $44.7 million in 2024, then skyrocketed by 46.07% to $65.3 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Operating Expenses are $65.3 million (Q4 2025), $43.3 million (Q3 2025), and $37.6 million (Q2 2025).